Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 19/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445354 | 1.00 | KCNJ1 (0.59) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL28291466 | 0.83 | KCNJ1 (0.55) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL30751853 | 0.78 | KCNJ1 (0.54) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20168056 | 0.78 | KCNJ1 (0.54) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL286348 | 0.78 | KCNJ1 (0.50) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL14786387 | 0.76 | KCNJ1 (0.43) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL16836137 | 0.74 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL29567627 | 0.74 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL286648 | 0.74 | ESR1 (0.64) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL29728674 | 0.74 | ESR1 (0.64) | KCNJ1KCNH2ACHESSTR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| CN-110678463-B | Substituted nitrogen-containing compounds | 百时美施贵宝公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3630752-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3630752-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-110678463-A | Substituted nitrogen-containing compounds | 百时美施贵宝公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20180346453-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2018-12-06 | — | — | US | disclosed |
| WO-2018222795-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | KCNJ1 562/4885KCNH2 382/4885ACHE 3686/4885 |
| US-20180346453-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | KCNJ1 562/4885KCNH2 382/4885ACHE 3686/4885 |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | KCNJ1 562/4885KCNH2 382/4885ACHE 3686/4885 |
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | KCNJ1 562/4885KCNH2 382/4885ACHE 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.